Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1NIH 1NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 41CNS 23Gastrointestinal 17Genitourinary 16Lymphoid 15Myeloid 12Endocrine 3Other hematologic neoplasm 2Gynecologic 2Dermatologic 2Other solid neoplasm 1Head & Neck 1

Conditions

Squamous Cell Carcinoma of Head and Neck 114Head and Neck Neoplasms 98Thyroid Neoplasms 55Salivary Gland Neoplasms 55Oropharyngeal Neoplasms 35Mouth Neoplasms 33Tongue Neoplasms 30Thyroid Cancer, Papillary 26Laryngeal Neoplasms 26Adenocarcinoma, Follicular 23Nasopharyngeal Neoplasms 22Carcinoma, Non-Small-Cell Lung 22Breast Neoplasms 21Hypopharyngeal Neoplasms 20Uterine Cervical Neoplasms 19Colonic Neoplasms 19Carcinoma, Medullary 16Rectal Neoplasms 15Pancreatic Neoplasms 15Esthesioneuroblastoma, Olfactory 15Esophageal Neoplasms 15Anus Neoplasms 15Neoplasms 14Lung Neoplasms 14Thyroid Carcinoma, Anaplastic 13Stomach Neoplasms 13Melanoma 13Carcinoma, Renal Cell 12Urinary Bladder Neoplasms 11Prostatic Neoplasms 11

Interventions

tipifarnib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Rhabdomyosarcoma × Head & Neck × Clear all
NCT04284774 2026-05-27

Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial

National Cancer Institute (NCI)

Phase 2 Active not recruiting
5 enrolled 9 charts
CNSDermatologicEndocrineGastrointestinalGenitourinaryHead & NeckLymphoidMyeloidSarcoma

Ependymoma, Glioma, Histiocytosis, Langerhans-Cell, Lymphoma, Non-Hodgkin, Medulloblastoma, Melanoma, Wilms Tumor, Neuroblastoma, Pheochromocytoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Thyroid Neoplasms, Hepatoblastoma, Neuroectodermal Tumors, Primitive, Peripheral, Rhabdoid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡